Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, PK and PD of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection.
Sponsor: Arbutus Biopharma Corporation
Listed as NCT05960240, this PHASE1 trial focuses on Chronic Hepatitis b and remains ongoing. Sponsored by Arbutus Biopharma Corporation, it has been updated 7 times since 2023, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2025 — Aug 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2023 — Mar 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Arbutus Biopharma Corporation
For direct contact, visit the study record on ClinicalTrials.gov .